Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,624 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 3,624 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $46.66, for a total value of $169,095.84. Following the sale, the director now owns 356,022 shares in the company, valued at approximately $16,611,986.52. The trade was a 1.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pro-Dex Trading Down 3.7 %

PDEX traded down $1.74 during midday trading on Tuesday, reaching $45.00. 15,511 shares of the company's stock traded hands, compared to its average volume of 31,039. The firm has a fifty day moving average of $48.04 and a two-hundred day moving average of $32.32. The stock has a market capitalization of $146.66 million, a price-to-earnings ratio of 29.22 and a beta of 0.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. Pro-Dex, Inc. has a 52 week low of $16.18 and a 52 week high of $59.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PDEX. Dimensional Fund Advisors LP raised its position in Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier's stock valued at $1,238,000 after purchasing an additional 3,067 shares during the last quarter. Geode Capital Management LLC raised its position in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock valued at $819,000 after purchasing an additional 2,296 shares during the last quarter. Bard Associates Inc. raised its position in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock valued at $406,000 after purchasing an additional 2,031 shares during the last quarter. FMR LLC raised its position in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock valued at $119,000 after purchasing an additional 1,028 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock worth $240,000 after acquiring an additional 900 shares in the last quarter. Institutional investors own 15.28% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PDEX. Ascendiant Capital Markets upped their price objective on Pro-Dex from $30.00 to $52.00 and gave the stock a "buy" rating in a report on Monday, November 11th. StockNews.com upgraded Pro-Dex from a "buy" rating to a "strong-buy" rating in a report on Saturday, December 14th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.